Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer

NCT00313248 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00313248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
November 30, 2008
Enrollment
65 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm